{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Dexamethasone+4mg", "query": { "intervention": "IV Dexamethasone 4mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IV+Dexamethasone+4mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-22T04:23:13.615Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01861340", "title": "Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Lenalidomide, Dexamethasone, and MEDI-551", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 20, "start_date": "2014-05", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2018-09-10", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01861340" }, { "nct_id": "NCT00738621", "title": "Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Postoperative Nausea and Vomiting" ], "interventions": [ { "name": "Aprepitant, Dexamethasone, Ondansetron", "type": "DRUG" }, { "name": "Aprepitant, Dexamethasone, Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scott and White Hospital & Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 100, "start_date": "2008-07", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 1, "location_summary": "Temple, Texas", "locations": [ { "city": "Temple", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00738621" }, { "nct_id": "NCT02294357", "title": "Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncotherapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2014-12", "completion_date": "2020-09-22", "has_results": false, "last_update_posted_date": "2023-11-01", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 7, "location_summary": "Encinitas, California • West Hills, California • West Hollywood, California + 4 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "West Hills", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Fleming Island", "state": "Florida" }, { "city": "Poughkeepsie", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02294357" }, { "nct_id": "NCT04208516", "title": "Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Postoperative Pain" ], "interventions": [ { "name": "Continuous Erector Spinae Plane Nerve Block", "type": "PROCEDURE" }, { "name": "Continuous Quadratus Lumborum Nerve Block", "type": "PROCEDURE" }, { "name": "Single Erector Spinae Plane Nerve Block", "type": "PROCEDURE" }, { "name": "Single Quadratus Lumborum Nerve Block", "type": "PROCEDURE" }, { "name": "Lidocaine IV", "type": "DRUG" }, { "name": "Ropivacaine 0.5% Injectable Solution", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Dexmedetomidine", "type": "DRUG" }, { "name": "Lidocaine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Jeremy Kearns", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 17, "start_date": "2021-05-26", "completion_date": "2022-08-18", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04208516" }, { "nct_id": "NCT03590652", "title": "Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2018-10-17", "completion_date": "2025-07-02", "has_results": false, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 4, "location_summary": "La Jolla, California • Los Angeles, California • Sacramento, California + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03590652" }, { "nct_id": "NCT05274113", "title": "Low Dose Dexamethasone for Distal Radius Fractures", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Post Operative Pain", "Distal Radius Fracture" ], "interventions": [ { "name": "Dexamethasone 4mg", "type": "DRUG" }, { "name": "Ropivacaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rothman Institute Orthopaedics", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2022-03-10", "completion_date": "2023-03-31", "has_results": false, "last_update_posted_date": "2022-03-10", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05274113" }, { "nct_id": "NCT01474915", "title": "Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Postoperative Nausea and Vomiting (PONV)", "Nausea" ], "interventions": [ { "name": "Aprepitant", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Promethazine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sergio Bergese", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 122, "start_date": "2007-06", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2013-12-03", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01474915" }, { "nct_id": "NCT04081545", "title": "Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Opioid Use, Unspecified", "Bariatric Surgery Candidate", "Anesthesia" ], "interventions": [ { "name": "Opioid Anesthetics", "type": "DRUG" }, { "name": "Non Opioid Analgesics", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Christine Oryhan", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 181, "start_date": "2019-12-24", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04081545" }, { "nct_id": "NCT02393157", "title": "Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma", "Burkitt Lymphoma", "Diffuse Large B-Cell Lymphoma", "Primary Mediastinal B-cell Lymphoma", "CD20+ Lymphoblastic Lymphoma", "Follicular Lymphoma, Grade III" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Liposomal ARA-C", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "31 Years", "sex": "ALL", "summary": "3 Years to 31 Years" }, "enrollment_count": 25, "start_date": "2015-08-21", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-08-08", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 1, "location_summary": "Valhalla, New York", "locations": [ { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02393157" }, { "nct_id": "NCT06312137", "title": "A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Sacituzumab tirumotecan", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rescue medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 780, "start_date": "2024-04-03", "completion_date": "2034-10-23", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-09-22T04:23:13.615Z", "location_count": 51, "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06312137" } ] }